Floatz logo

Icotinib

Bronchial Neoplasms

Sun Yat-sen UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Bronchial Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 3BB
Vinorelbine
University of Turin, Italy
Phase 3B
Docetaxel
University of Turin, Italy
Phase 3B
ETOPOSIDE
Nanfang Hospital, Southern Medical University
Phase 2CCC
ALECTINIB
Hoffmann-La Roche
Phase 2CCC

View all 17 →

Same molecule, other indications

Icotinib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →